Clinical Trial

A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies

Study acronym: ARC-27
Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The primary purpose of this study is to assess the safety and tolerability of AB801 in participants with advanced malignancies, and to determine a recommended AB801 dose for expansion.
Protocol Amendment History 30 amendments
This ClinicalTrials.gov record has been amended 30 times since 2023-11-01; most recent amendment 2026-06-30.
Status change: Recruiting → Active, Not Recruiting 2026-01-27
Status change: Not Yet Recruiting → Recruiting 2024-01-19
Trial Details
NCT Number NCT06120075
Lead Sponsor Arcus Biosciences, Inc.
Conditions Advanced Cancer
Enrollment 91 participants
Start Date 2024-01-19
Primary Completion 2026-11 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2026-08-13